DARATUMUMAB
Carfilzomib
The First Affiliated Hospital of Soochow Universitymonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Carfilzomib cohort.
Same molecule, other indications
DARATUMUMAB is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →